Korsana Biosciences
KRSA
37.56
+2.11
+5.95%
Korsana Biosciences
US · KRSA
#2830 by market cap
Listed 1970
37.56
+2.11
+5.95%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Revenue annual, last 2 years
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | 53.00K | 4.51M |
| Research & development | 56.00K | 32.79M |
| Operating profit | -109.00K | -37.29M |
| Pretax profit | -88.00K | -35.64M |
| Tax | -- | -- |
| Net profit | -88.00K | -35.64M |
| Basic EPS | 0 | -7 |
| Diluted EPS | -0.02 | -7.07 |
| Line item | 2025-09 | 2025-12 | 2026-06 | 2026-09 |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 1.48M | 2.92M | 2.94M | 6.14M |
| Research & development | 20.48M | 12.05M | 15.51M | 42.14M |
| Operating profit | -21.96M | -14.97M | -18.45M | -48.27M |
| Pretax profit | -21.72M | -13.69M | -17.36M | -46.43M |
| Tax | -- | -- | -- | -- |
| Net profit | -21.72M | -13.69M | -17.36M | -46.43M |
| Basic EPS | -4 | -3 | -3 | -3 |
| Diluted EPS | -4.27 | -2.69 | -3.42 | -3.19 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 10.11M | 154.60M |
| Cash & ST investments | 10.11M | 154.14M |
| Inventory | -- | -- |
| Total assets | 10.11M | 154.60M |
| Total current liabilities | 78.00K | 12.49M |
| Short-term debt | -- | -- |
| Long-term debt | -- | -- |
| Total liabilities | 10,042,000.00 | 188,564,000.00 |
| Total equity | 66.00K | -33.97M |
| Retained earnings | -88.00K | -35.73M |
| Line item | 2025-09 | 2025-12 | 2026-06 | 2026-09 |
|---|---|---|---|---|
| Total current assets | -- | 154.60M | 121.81M | 460.65M |
| Cash & ST investments | -- | 154.14M | 121.17M | 456.22M |
| Inventory | -- | -- | -- | -- |
| Total assets | -- | 154.60M | 126.16M | 462.08M |
| Total current liabilities | -- | 12.49M | 12.55M | 44.20M |
| Short-term debt | -- | -- | 191.00K | 287.00K |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | -- | 188,564,000.00 | 189,434,000.00 | 70,521,000.00 |
| Total equity | -- | -33.97M | -63.28M | 391.56M |
| Retained earnings | -- | -35.73M | -66.60M | -113.03M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | 44.00K | -22.41M |
| Depreciation & amortization | -- | -- |
| Free cash flow | 44.00K | -22.41M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 10.11M | 154.14M |
| Line item | 2025-09 | 2025-12 | 2026-06 | 2026-09 |
|---|---|---|---|---|
| Operating cash flow | -- | -10.61M | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- |
| Free cash flow | -- | -10.61M | -- | -- |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | -- | 154.14M | -- | -- |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -133.33 | -- |
| ROA %i | -0.87 | -43.28 |
| ROIC %i | -165.15 | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 129.59 | 12.38 |
| Quick ratioi | 129.59 | 12.34 |
| Debt / assetsi | -- | -- |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-09 | 2025-12 | 2026-06 | 2026-09 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -23.24 |
| ROA %i | -- | -43.28 | -- | -19.69 |
| ROIC %i | -- | -- | -- | -24.55 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | -- | 12.38 | 9.71 | 10.42 |
| Quick ratioi | -- | 12.34 | 9.65 | 10.32 |
| Debt / assetsi | -- | -- | 0.88 | 0.28 |
| LT debt / equityi | -- | -- | -- | 0.25 |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Korsana Biosciences discussion 0 comments